A Phase 4 interventional study of Somatropin in Short Stature, Idiopathic, Infant, Small for Gestational Age and Growth Hormone Deficiency, sponsored by LG Life Sciences. Completed at 1 site in Korea, Republic of. Open to participants aged 4 Years to 15 Years. Per ClinicalTrials.gov, last updated 2019-01-03.
Sponsored by LG Life Sciences (part of LG Chem) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing Human Growth Hormone in Dwarfism — none open to participants now, 1 under way, none of them phase 3. Human Growth Hormone · Dwarfism.
Among the 15 studies testing Human Growth Hormone in Dwarfism, this one is the 6th largest by enrollment, is the only one that started in 2016, is one of 4 in phase 4, and was the 11th registered.
99 studies on the registry are indexed under Dwarfism; 12 are open to participants now.
Browse Dwarfism studies →None of the 15 studies testing Human Growth Hormone in Dwarfism is open now. The open studies under Dwarfism, anywhere →
Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 7 Dwarfism studies recruiting now, 1 sets no upper age limit and 5 stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 4 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 7 · Phase 4 4
First in 1989; this study’s year is marked. 1 started in 2016.
This study's enrollment of 116 is above the median of 60 across 66 interventional studies indexed under Dwarfism.
Median enrollment 68 across the 15 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under LG Life Sciences, one of the names counted as LG Chem. Under that name alone:
LG Life Sciences is the lead sponsor of 78 studies on the registry; none are open to participants now.
LG Chem has 1 study filed under Dwarfism — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing Human Growth Hormone in Dwarfism, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the ease of use, preference, and safety after 8 weeks subcutaneous administration of EutropinPen Inj. in patients pretreated with recombinant human growth hormone by reusable device.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects who has diseases below on screening visit
Drug: Somatropin
Ease of use for EutropinPen Inj. against previous reusable device assessed by a questionnaire.
Time frame: Day 57
Preference for EutropinPen Inj. against previous reusable device assessed by a questionnaire.
Time frame: Day 57
Benefits of EutropinPen inj. assessed by a questionnaire
1. Ease of use 2. Unit 3. High dose packing 4. Grip 5. Design 6. Less pain
Time frame: Day 57
Fear assessed by a questionnaire
Ask of fearness how the child feels about the needle
Time frame: Screening, Day 57
Ease of use for EutropinPen Inj. at each injection step assessed by a questionnaire
1. Ask ease of use at each injection step (1\~5 pts) 2. Preparation time for injection
Time frame: Screening, Day 57
Treatment compliance of EutropinPen Inj. (%)
Time frame: Day 57
Plan to share: Undecided
Ran from Aug 2016 to primary completion in Dec 2017, 16 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone